Canada's approach to drug safety during pregnancy is a critical issue that demands urgent attention and reform. The current system, marked by a 27-year lag in determining medication safety, is a stark reminder of the country's structural failure to protect pregnant women and their unborn children. This delay is not just a gap; it's a systemic issue that has far-reaching consequences, as highlighted by the fact that over 80% of prescription drugs approved in Canada over the past two decades lack adequate safety data for pregnant women. This is particularly concerning given that approximately 80% of pregnant women take at least one medication, leaving them and their children vulnerable to unknown risks.
The proposed Bill S-243, championed by Senator Danièle Henkel, is a step in the right direction. By strengthening oversight, improving data collection, and enhancing accountability, it aims to shift the focus from tolerating uncertainty to actively addressing it. However, the bill also exposes a critical blind spot: what happens when medications are widely used by populations that were never properly studied. This is not a niche issue; it affects most women who require medications during pregnancy for chronic conditions such as depression, autoimmune diseases, high blood pressure, epilepsy, diabetes, or asthma, or for pregnancy-related conditions like nausea and infections.
The problem is not just about data; it's about equity. Women's health, particularly maternal health, has often been treated as peripheral in research and policy. This lack of evidence in pregnancy is not accidental; it is the predictable result of that neglect. Pregnant women should not have to make critical medical decisions in an evidence vacuum. Canada has the expertise and some data, but what it needs now is focus and the political will to act.
One of the key challenges is the chronic underinvestment in women's health research. Less than 7% of publicly funded health research in Canada is dedicated to women's health, placing the country near the bottom of the G7. This underinvestment has led to a reactive system that relies on slow, fragmented post-market data to detect risks that should have been understood much earlier. The consequences of delay are not theoretical; during the COVID-19 pandemic, slow access to real-world data and the delayed inclusion of pregnant women in vaccine trials contributed to inconsistent recommendations and widespread uncertainty, eroding trust in public health institutions.
To address this issue, Canada must invest in national research infrastructure, ensure the ethical inclusion of pregnant women in research, and commit to translating evidence into clear, practical clinical guidance. Equally critical is access to timely, integrated data across all provinces and territories. The federal interoperability legislation Bill S-5 is an important step toward breaking down data silos and enabling secure access to health information across jurisdictions. Without this foundation, even well-intentioned policies risk falling short.
In conclusion, Canada's blind spot on drug safety in pregnancy is a systemic issue that requires a multi-faceted approach. By addressing the chronic underinvestment in women's health research, investing in national research infrastructure, and ensuring timely, integrated data access, Canada can lead the way in protecting pregnant women and their children. It's time to shift the focus from tolerating uncertainty to actively addressing it, and Bill S-243 is a crucial step in that direction.
